TRIM 67876

National Insulin Form Pilot Advisory Group

Meeting 1, 2.00pm to 4.00pm (AEST), Tuesday 28August 2012

Teleconference

Meeting 1

DraftOutcomes

Members

Mr Graham Bedford / Medication Safety Program Manager, Chair
Dr Peter Donovan / Staff Specialist, Internal Medicine and Aged Care, Staff Specialist, Clinical Pharmacology, Royal Brisbane and Women's Hospital
Dr Merryn Thomae / Staff Consultant / General Physician and Endocrinologist, MaterAdultHospital
Dr Nathalie Van Havre / General Physician, MaterAdultHospital
Prof Charles Mitchell / Safe Medication Practice Unit, Queensland Health
Ms Carol Reid / Safe Medication Practice Unit, Medication Services Queensland

Office of the Commission

Ms Helen Stark / Senior Project Officer, Medication Safety Program

Apologies

Ms Rebecca Donovan / Network Manager, Endocrine, Agency for Clinical Innovation
Prof Trisha Dunning / Chair in Nursing (Barwon Health), Centre for Exceptional Nursing Through Research Excellence
Mr Daniel Lalor / Project Manager, Medication Safety, Clinical Excellence Commission, NSW
Ms Fiona McIver / Medication Safety Officer, Queensland Health
Ms Helen Leach / Program Manager, Quality Use of Medicines Program, Department of Health, Victoria

Meeting outcomes

  1. Members were welcomed and apologies noted. Mr Bedford advised that he would chair the first meeting until a formal decision had been made on a chair for the group.
  2. There were no conflicts of interestdeclared.
  3. Terms of reference

Members noted the terms of reference. Members considered that the current membership needs to be broadened to include a consumer and/or medical officer with hospital experience in diabetes management. The inclusion of anEndocrinologist from a national Diabetes organisation was also seen as desirable.

Action 1: The Commissionagreed to broaden representation on the group for the next meeting to be held late September.

4.Project Plan

Members noted Project Plan and the history of the development of the national subcutaneous insulin form. Members noted that this group (NIFPAG) would replace the original advisory group which was known as the National Insulin Prescribing and Administering Committee (NIPAC). Members noted the project timelines and that there would be some flexibility with the timelines based on advice from the group.

5. Pilot materials

Members noted availability of the pilot materials and that the form had been extensively refined through its use in Queensland. This, combined with the heuristic analysis described at the meeting, ensured the form and associated pilot materials were well tested.

Prof Mitchell advised that as Queensland public hospitals were still using the previous version of the form they would not be participating in the national pilot. He also advised that hospitals would want to continue to use the pilot form after the end of the pilot if they found it useful and this needed to be considered in the hospital’s planning.

6.National Subcutaneous Insulin Form Pilot Audit Parameters

Members noted the audit parameters. It was agreed that the analysis should provide information on the following:

  • Number of hypoglycaemic episodes
  • Number of BGL readings over 20
  • Number of readings in BGL range of 12-20.

Members agreed to add the following parameters to the audit:

  • Was a HbA1c test performed? Yes/No
  • What is the HbA1c reading?

Members agreed that it would be useful to have a hospital conduct a “trial” of the audit data elements and the audit tool to ensure the data elements are collectable and the audit tool works. Mater Health Services offered to be a trial site for this purpose.

Action 2: Commission to revise the audit parameters and commence work on developing the audit tool.

7.Other business

There was no other business.

8. Next Meeting

The next meeting will be held by teleconference at 1400 AEST on Thursday 27 September 2012.

1

National Insulin Form Pilot Advisory Group Meeting 128 August 2012